Project Grant DP2AI184606
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$500K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of ZNF proteins in establishing and maintaining HIV latency. The two-year project aims to evaluate how ZNF proteins impact the epigenetic landscape in primary CD4+ T cells and explore mechanisms of HIV latency...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize HIV reservoirs in macrophages and investigate mechanisms by which these cells resist antibody-dependent cellular cytotoxicity (ADCC). The $243,713 award to the University of Massachusetts Medical School aims to: 1) determine how HIV accessory proteins Nef and Vpu differentially regulate NK cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $848,839 to the University of Massachusetts Medical School (UMass Medical) to investigate new mechanisms by which HIV accessory proteins mediate control of natural killer (NK) cell function. The key objectives are to identify novel HIV-regulated NK cell ligands, define how the HIV Vif protein regulates MHC-I...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,583,665 to Boston Medical Center Corporation to investigate the role of defective HIV proviruses in driving persistent inflammation in HIV-infected CD4+ T cells and macrophages. The research aims to: 1) Determine if persistent expression of cryptic HIV-1 RNAs promotes innate immune activities, 2) Examine whether HIV-1 and HIV-2...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...